US Patent 8,758,733: Claim Scope, Exclusivity, Litigation Risk, and Bimatoprost Patent Landscape

US Patent 8,758,733 protects methods of using 0.03% w/v bimatoprost to prevent or treat chemotherapy-associated eyelash loss. The two independent claims cover treatment before, during, or after chemotherapy. The patent does not claim bimatoprost as a chemical compound, a general eyelash-growth agent, or the Latisse formulation broadly. Its commercial value depends on whether a product is marketed or prescribed for chemotherapy-associated eyelash hypotrichosis and whether the accused use falls within the claimed timing, concentration, route, and patient population.

What does US Patent 8,758,733 claim?

The patent has two independent method claims:

Claim	Independent or dependent	Core subject matter
1	Independent	Growing eyelashes in chemotherapy patients using 0.03% w/v bimatoprost applied to the eyelids before, during, or after chemotherapy
13	Independent	Treating chemotherapy-associated eyelash loss using 0.03% w/v bimatoprost applied before, during, or after chemotherapy

Claims 1 and 13 are substantially overlapping. Claim 1 emphasizes eyelash growth. Claim 13 emphasizes treatment of eyelash loss. Both require:

A chemotherapy patient or patient undergoing chemotherapy.
Application to the eyelids.
Bimatoprost at 0.03% w/v.
Application before, during, or after chemotherapy.

The claims are method-of-use claims. They do not cover every manufacture, sale, or use of bimatoprost. Infringement generally requires performance of the claimed steps or inducement of another party to perform them.

How broad is the chemotherapy limitation?

The chemotherapy limitation is central to the patent’s scope. A use directed solely to idiopathic eyelash hypotrichosis would not literally satisfy the chemotherapy-patient limitation.

The claims use broad timing language:

Before chemotherapy
During chemotherapy
After chemotherapy

The wording “one selected from the group consisting of” ordinarily permits selection of one listed alternative. It does not necessarily require use in all three periods. A regimen initiated after chemotherapy can therefore fall within claims 1 and 13 if the other limitations are met.

The claims do not identify:

A specific chemotherapy drug
A specific cancer type
A specific chemotherapy schedule
A minimum degree of eyelash loss
A specific duration of chemotherapy
A particular formulation excipient
A particular applicator
A required clinical endpoint, except where added by dependent claims

The absence of those limitations increases the potential patient-population breadth. A product promoted for chemotherapy-related eyelash loss could present risk even if the product is intended for only one cancer type or one chemotherapy regimen.

What limitations are added by the dependent claims?

The dependent claims narrow the independent claims through dosing frequency, treatment duration, application site, outcome, combination therapy, and comparative safety.

Claims	Added limitation	Practical effect
2, 14	At least once daily	Captures once-daily and more frequent use
3, 6, 15	Longer, thicker, darker, or increased number or length of eyelashes versus untreated patients	Adds an outcome or comparison limitation
4, 16	Treatment for at least six months after chemotherapy	Covers extended post-treatment regimens
5, 17	Treatment for at least 12 months after chemotherapy	Narrower long-duration claims
7	Bimatoprost applied during and after chemotherapy	Requires two timing phases
8	Twice-daily application	Narrower dosing regimen
9	Upper or lower eyelid margin of each eye	Adds anatomical application detail
10	Effective treatment of post-chemotherapeutic hypotrichosis	Narrows the disease condition
11	Concurrent Minoxidil or Propecia	Combination-treatment claim
12	Lower incidence of specified adverse events than in idiopathic hypotrichosis patients	Comparative safety limitation
18	Once-daily application	Narrower than claim 14
19	Application to the upper eyelid	Specific site
20	Application to the upper or lower eyelid	Broader than claim 19 but dependent on once-daily use

Claims 2 and 14 are important commercially because once-daily eyelid application is consistent with the conventional use pattern for bimatoprost eyelash products. Claims 18 to 20 create additional combinations around once-daily use and eyelid location.

Does the patent cover Latisse or bimatoprost generally?

No. The claims do not cover bimatoprost as a molecule or all uses of Latisse.

Latisse is a 0.03% bimatoprost ophthalmic solution approved by the FDA for hypotrichosis of the eyelashes. Its labeled indication concerns inadequate or insufficient eyelashes and does not establish a chemotherapy-specific indication.[1] Patent 8,758,733 is directed to a particular patient population and therapeutic use.

The distinction is commercially significant:

Use	Likely relevance of US 8,758,733
Idiopathic eyelash hypotrichosis	Generally outside the express chemotherapy limitation
Chemotherapy-associated eyelash loss	Directly within the patent’s subject matter
Glaucoma treatment with ophthalmic bimatoprost	Outside the claimed eyelash-growth method
Use before chemotherapy	Expressly covered
Use during chemotherapy	Expressly covered
Use after chemotherapy	Expressly covered
Sale of bimatoprost without chemotherapy-related promotion	More difficult to link to direct infringement, but inducement risk may remain
Compounded or reformulated bimatoprost at a different concentration	Potentially outside the literal 0.03% limitation, subject to claim construction and equivalents

When does US Patent 8,758,733 lose exclusivity?

The patent was issued on June 24, 2014. Its term is governed principally by the earliest effective nonprovisional filing date and any applicable patent-term adjustment or terminal disclaimer. A reliable expiration date must be taken from the USPTO Patent Center record and the patent’s front-page term data, not calculated from the issue date alone.[2]

The relevant exclusivity framework is:

Exclusivity right	Relevance
Bimatoprost compound patent	Separate from the chemotherapy-use claims and historically associated with earlier expiry
Latisse formulation or use patents	May affect products for general eyelash hypotrichosis
US 8,758,733	Focuses on chemotherapy-associated eyelash loss
FDA orphan exclusivity	Not established by the supplied claims
FDA new chemical entity exclusivity	Not applicable to bimatoprost as an old active ingredient
Pediatric exclusivity	No basis is established in the supplied record
Patent-term adjustment	Must be confirmed from USPTO records
Patent-term extension	Must be confirmed separately; method-of-use patents generally require a specific regulatory basis

The practical conclusion is that US 8,758,733 cannot be treated as having the same expiration date as the original bimatoprost compound patent. Its term is a separate issue.

What is the Orange Book status of US Patent 8,758,733?

Orange Book listing depends on whether the patent claims the approved drug, an approved formulation, or an approved method of use for the relevant NDA. The FDA Orange Book lists patents submitted by NDA holders and accepted under the applicable statutory framework.[3]

The claims supplied here are directed to chemotherapy-associated eyelash loss. The FDA-approved Latisse indication is eyelash hypotrichosis, without a chemotherapy-specific indication in the product labeling.[1] That creates a potential listing issue: a patent directed to a use outside the approved labeling may not provide the same Orange Book position as a patent that claims the approved indication.

The supplied claim text alone does not establish that US 8,758,733 is listed in the Orange Book for NDA 022369. The listing status should be assessed separately from the patent’s validity and infringement scope. A patent can be enforceable without being listed in the Orange Book, although the absence of listing changes the ANDA-based litigation and notice framework.

Are Paragraph IV challenges available?

A Paragraph IV challenge is available when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or will not be infringed. The mechanism depends on the patent being listed for the relevant reference product and the ANDA applicant seeking approval for a use covered by that listing.[4]

For US 8,758,733, the analysis has two branches:

If the patent is not listed for the relevant bimatoprost NDA, it may not generate a conventional Orange Book Paragraph IV certification.
If it is listed and the ANDA’s proposed labeling includes chemotherapy-associated eyelash loss, the applicant could face a Paragraph IV dispute.

A generic applicant may also attempt a section viii statement carving out a patented method of use. That strategy depends on the labeling language and whether the proposed label can omit the patented chemotherapy-related use while retaining approval for noninfringing uses.

A product label that expressly states use for chemotherapy-associated eyelash loss would create greater risk than a label limited to general eyelash hypotrichosis. Promotional materials, medical-affairs communications, reimbursement coding, and patient-support programs can also affect induced-infringement exposure.

What formulation patents and manufacturing barriers matter?

US 8,758,733 is not primarily a formulation patent. Its claims identify 0.03% w/v bimatoprost but do not, in the supplied text, require a particular preservative, vehicle, pH, container, applicator, or manufacturing process.

The key technical distinction is:

Concentration limitation: 0.03% w/v bimatoprost.
Formulation limitation: a defined composition with specified inactive ingredients or physical properties.
Manufacturing limitation: a defined process for producing or filling the product.

A competing product could potentially avoid literal infringement by using a concentration other than 0.03% w/v. That approach carries regulatory and clinical consequences because a different concentration or formulation may require new safety, efficacy, stability, or bridging support.

Manufacturing freedom to operate must therefore be analyzed across separate patent families covering:

Bimatoprost synthesis and intermediates
Ophthalmic solutions
Preservative systems
Low-dose topical formulations
Applicators and packaging
Stability and shelf-life
Manufacturing and filling processes

The chemotherapy-use patent alone does not establish freedom to operate for any particular generic or biosimilar-like product. Bimatoprost is a small molecule, so biosimilar regulation is not applicable. A competing product would ordinarily follow an ANDA, 505(b)(2), or full NDA pathway depending on formulation, labeling, and reliance on the reference product.

Which companies are most exposed to the patent?

The most exposed parties are:

Party	Exposure
NDA holder or licensee promoting chemotherapy-related eyelash recovery	High
Generic applicant seeking a chemotherapy-related label	High
Compounding pharmacy advertising chemotherapy eyelash treatment	Potentially high
Oncology practice using bimatoprost off-label without promotion	Fact-dependent
Manufacturer selling bimatoprost for glaucoma	Low under these claims
Manufacturer marketing general eyelash hypotrichosis treatment	Lower, unless chemotherapy use is promoted
Applicator or excipient supplier	Usually indirect and dependent on inducement or contribution theories

The patent’s commercial leverage is stronger against targeted oncology or survivorship products than against broad ophthalmic bimatoprost products with no chemotherapy-related labeling or promotion.

What litigation and settlement issues should be reviewed?

The supplied information does not establish a litigation history, settlement agreement, consent judgment, or license involving US 8,758,733. Patent-risk review should distinguish among:

District-court infringement litigation
Hatch-Waxman litigation
Inter partes review
Post-grant review
Patent-term disputes
ANDA settlements
Covenants not to sue
Field-of-use licenses
Agreements limiting oncology promotion

A settlement could materially alter market-entry timing even if the patent remains unexpired. Conversely, the absence of a known lawsuit would not establish that the patent is unenforceable or commercially irrelevant.

Validity challenges would likely focus on:

Written description and enablement for chemotherapy patients.
Obviousness based on bimatoprost’s known eyelash-growth effects and chemotherapy-associated eyelash loss.
Definiteness of comparative limitations in claims 3, 6, 12, and 15.
Scope and support for the claimed treatment periods.
Double-patenting or terminal-disclaimer issues.
Whether the claimed clinical outcomes are inherent or require proof during infringement litigation.

How strong is the patent estate?

The estate appears strongest as a targeted method-of-use position and weaker as a platform monopoly.

Attribute	Assessment
Chemical composition protection	None apparent from the supplied claims
Broad product protection	Limited
Chemotherapy-use protection	Direct and commercially relevant
Patient-population breadth	Broad because no cancer or chemotherapy agent is specified
Dosing flexibility	Broad in independent claims; narrowed in dependent claims
Formulation coverage	Limited
Manufacturing coverage	None apparent
Design-around potential	Moderate, particularly through labeling, concentration, and use restrictions
Biosimilar relevance	None
ANDA relevance	Dependent on Orange Book listing and proposed labeling
Litigation leverage	Highest where chemotherapy use is expressly promoted

Key Takeaways

US Patent 8,758,733 is a chemotherapy-specific bimatoprost method-of-use patent.
Claims 1 and 13 are the principal enforcement claims.
The claims cover use before, during, or after chemotherapy at 0.03% w/v applied to the eyelids.
The patent does not claim bimatoprost generally or all Latisse uses.
Once-daily post-chemotherapy treatment is captured by multiple dependent claims.
The patent is not a formulation or manufacturing patent based on the supplied claims.
Bimatoprost is a small molecule, so biosimilar analysis does not apply.
Paragraph IV exposure depends on Orange Book listing and the ANDA’s proposed labeling.
Off-label oncology use, promotional conduct, and induced infringement require separate factual analysis.
The patent’s exact expiration date and Orange Book status must be confirmed from USPTO and FDA records.

FAQs About US Patent 8,758,733

Does US Patent 8,758,733 cover Latisse for every patient?

No. The claims are directed to chemotherapy patients or patients undergoing chemotherapy. General use for idiopathic eyelash hypotrichosis is not expressly covered by the supplied claims.

Can a competitor avoid the patent by using bimatoprost once daily?

No. Once-daily use is expressly covered by claims 2, 14, and 18 when the other limitations are satisfied.

Does the patent cover use only after chemotherapy?

Yes. The independent claims expressly include post-chemotherapy use. Claims 4, 5, 16, and 17 further cover treatment for at least six or 12 months after chemotherapy.

Is a different bimatoprost concentration automatically outside the patent?

A concentration materially different from 0.03% w/v may avoid literal infringement of the supplied claims, but equivalence, regulatory requirements, and other patent families must be assessed separately.

Can a generic obtain approval without challenging the patent?

Potentially. A generic applicant may use a labeling carve-out if the patented chemotherapy-related use can be omitted and the remaining proposed use is approvable. That outcome depends on the Orange Book listing and FDA labeling analysis.

References

U.S. Food and Drug Administration. (2008). Latisse (bimatoprost ophthalmic solution) 0.03% prescribing information.
United States Patent and Trademark Office. (2014). U.S. Patent No. 8,758,733, methods of treating chemotherapy-associated eyelash loss.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application regulations and patent certifications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2003207843	⤷ Start Trial
Australia	2008203212	⤷ Start Trial
Australia	2010227111	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,758,733

Summary for Patent: 8,758,733